Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-MD in AL-Amyloidosis or Light Chain Deposition Disease
NCT00520767Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Sep 2007
- Primary completion
- Oct 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in primary systemic amyloidosis, light chain deposition disease (LCDD), sponsored by Barbara Ann Karmanos Cancer Institute. Started Sep 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
primary systemic amyloidosislight chain deposition disease (LCDD)
Beyond the preview
Go deeper on NCT00520767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520767.